Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & Prior Auth updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    Local-246 Prescription Drug Formulary — Covered Drugs, Tiers, and Utilization Management

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth Local 246 2026 prescription drug formulary describing covered drugs, tiers, and plan-level utilization management requirements (e.g., prior authorization, quantity limits, step therapy, specialty designation) for affected members and their providers.

    Policy Summary
    PayerEmblemHealth
    PolicyLocal-246 Prescription Drug Formulary — Covered Drugs, Tiers, and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionSubmit prior authorization, quantity‑limit, specialty or step‑therapy requests when a drug line is annotated PA, QL, SP, LA, or ST.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01effective
    L246formulary id
    PA/QL/ST/SP/LAutilization controls
    availablehome delivery
    20+entries in excerpt

    Coverage Rules and Formulary Entries

    General coverage rule

    Coverage is provided according to formulary tier and utilization management annotations; drugs annotated with PA, QL, ST, SP, or LA are subject to additional requirements.

    Formulary coverage general rule: Drug is covered when it is on the formulary and any applicable utilization management requirements (PA, QL, ST, SP, LA) are satisfied.

    Providers must follow PA/QL/ST/LA/SP requirements where indicated; failure to obtain required authorizations or to adhere to listed quantity limits may result in denial.

    Formulary coverage entries

    Coverage and benefit tier apply per drug as listed; many drugs are covered subject to listed Requirements/Limits.

    Per-drug coverage condition: Drug coverage is determined by the Drug Tier and the specific Requirements/Limits shown on the formulary line item (examples: PA, QL, LA, SP, ST).

    Refer to each drug line for exact QL amounts, PA/LA/SP flags, and any ST annotations; specialty or limited-distribution products often require PA and specialty pharmacy routing.

    Policy Summary
    PayerEmblemHealth
    PolicyLocal-246 Prescription Drug Formulary — Covered Drugs, Tiers, and Utilization Management
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionSubmit prior authorization, quantity‑limit, specialty or step‑therapy requests when a drug line is annotated PA, QL, SP, LA, or ST.
    SourceLink
    On This Page
    Coverage Rules and Formulary EntriesDrug Listings and Code TablesAuthorization, Documentation, and Provider StepsPer-Drug Quantity LimitsSpecialty Pharmacy and DistributionFormulary Background and ScopeDefinitions and AbbreviationsStep Therapy RequirementsDocument Dates and Revision Notes

    This formulary excerpt is not a guarantee of coverage. Not all drugs in this list are paid for by all drug benefit plans; members and providers must check the member’s specific Certificate of Coverage or contact Member Services to confirm whether a particular drug, formulation, or tier is covered and to determine applicable copays or other cost-sharing.

    The listing in this segment primarily enumerates per‑product Requirements/Limits flags such as PA (prior authorization), LA (limited availability), SP (specialty pharmacy), and QL (quantity limits). No explicit blanket exclusions are stated in these chunks; instead, each line item shows the utilization management annotations that apply to that product.

    No explicit exclusions are shown in this extract. Absence of a Requirements/Limits annotation on a given line does not itself guarantee coverage beyond the member’s ordinary benefit terms — coverage remains subject to the plan’s Certificate of Coverage and any drug‑specific utilization management shown on the formulary.

    This excerpt does not contain any statements declaring therapies or products to be not medically necessary. Coverage determinations should follow the plan’s established medical necessity and prior authorization processes where referenced by per‑drug Requirements/Limits.

    Drug Listings and Code Tables

    Selected specialty and limited-availability medications shownmixedCovered
    ARIKAYCE - amikacin sulfate liposome inhal susp 590 mg/8.4mlDrug listed with Requirements/Limits = LA, PA, QL (28 vials/28 days), SP
    TOBI PODHALER - tobramycin inhal cap 28 mgRequirements/Limits = LA, SP
    TOBRAMYCIN - tobramycin nebu soln 300 mg/5mlRequirements/Limits = SP
    KITABIS PAK - tobramycin nebu soln 300 mg/5mlRequirements/Limits = LA, SP
    Covered drug list excerpts by classmixedCovered
    AMOXICILLINmultiple formulations and strengths listed with Tier assignments (1-2)
    AMOXICILLIN & K CLAVULANATEmultiple formulations and strengths listed with Tier assignments (1-2)
    AUGMENTINlisted (tier 2 for certain formulations)
    CEFADROXIL, CEFIXIME, CEFAClOR, CEFPODOXIME PROXETIL, etc.numerous cephalosporins listed with tiers
    AZITHROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN, FIDAXOMICINmacrolides and related agents listed with tiers
    TETRACYCLINES (doxycycline, minocycline, tetracycline)listed with tiers and some LA annotations
    FLUOROQUINOLONES (ciprofloxacin, levofloxacin, moxifloxacin, etc.)listed with tiers
    Selected listed products (partial)NDC | mixed
    migalastat hcl cap 123 mgGALAFOLD - migalastat hcl cap 123 mg (base equivalent) (Drug Tier = 2); Requirements/Limits = LA, PA, QL (14 capsules/28 days), SP
    crinecerfont cap 25 mg, 50 mg, 100 mgCRENESSITY - crinecerfont cap 25 mg, 50 mg, 100 mg (Drug Tier = 2); Requirements/Limits = LA, PA, QL (60 capsules/30 days), SP
    crinecerfont oral soln 50 mg/mlCRENESSITY - crinecerfont oral soln 50 mg/ml (Drug Tier = 2); Requirements/Limits = LA, PA, QL (120 mls/30 days), SP
    Additional products with QL/STmixed
    tolvaptan tab 15 mg, 30 mgJYNARQUE / tolvaptan listings with QL (56 tablets/28 days; 60 tablets/30 days; 30 tablets/30 days), LA, PA, SP where specified
    finerenone tab 10 mg, 20 mg, 40 mgKERENDIA - finerenone tab 10 mg, 20 mg, 40 mg (Drug Tier = 2); Requirements/Limits = QL (30 tablets/30 days), ST
    Cardiovascular and antihypertensive drugs (bulk listing)mixed
    digoxin (various forms/strengths)DIGOXIN - multiple formulations listed; some require PA
    numerous cardiovascular agentsMany antihypertensives, beta blockers, calcium channel blockers, antiarrhythmics with tiers and occasional QL/PA/LA/SP flags
    NDC/CPT/HCPCS codesmixed
    No codes listed
    Formulary requirement codesmixed
    LALimited Access (formulary designation)
    PAPrior Authorization required
    QLQuantity Limit
    SPSpecialty Pharmacy
    Formulary items (no procedural or billing codes in this section)mixed
    No codes listed
    inv-15: ARIKAYCE quantity limit — 28 vials/28 days
    ARIKAYCE quantity limit28 vials/28 days
    Formulary flagsRequirements/Limits = LA, PA, QL; Specialty Pharmacy (SP) noted
    Drug formulationamikacin sulfate liposome inhalation suspension 590 mg/8.4 mL
    inv-16: Quantity limits examples
    Example: 14 capsules/28 daysListed as example QL in quantity-limits examples
    Example: 56 tablets/28 daysShown for select products (e.g., TRIKAFTA alternative packet counts/other entries)
    Example: 60 tablets/30 daysCommon QL observed for some therapy packs and strengths
    Example: 30 tablets/30 daysFrequent QL (e.g., BIKTARVY, KERENDIA, other oral tablets)
    Example: 120 tablets/30 daysUsed for higher-count QLs in certain products (example entries)
    inv-17: estradiol vaginal cream limit — 255 grams/365 days
    Estradiol vaginal cream (Estrace) limit255 grams/365 days
    FormulationEstradiol vaginal cream 0.01%
    Coverage noteQuantity limit enforced per Requirements/Limits entry
    inv-18: MYRBETRIQ granules limit — 300 mls/28 days
    MYRBETRIQ granules (oral suspension) limit300 mls/28 days
    Alternate formulation QLMYRBETRIQ tablets QL = 30 tablets/30 days (separate entry)
    Formulary annotationRequirements/Limits indicate QL for granules formulation
    inv-19: VOWST limit — 12 capsules/365 days
    VOWST limit12 capsules/365 days
    FormulationVOWST — fecal microbiota spores, live-brpk capsules
    Requirements/LimitsLA, PA, QL noted in formulary entry
    inv-20: Common quantity limits
    QL (30 tablets/30 days)Common quantity-limit observed for many oral tablet products
    QL (60 tablets/30 days)Applied to certain higher-count tablet formulations and strengths
    QL (90 tablets/30 days)Used for some chronic oral medications (example entries)
    QL (480 mls/30 days)Example for liquid formulations (e.g., certain oral solutions)
    QL (540 mls/30 days)Used for sodium oxybate and similar oral solutions
    inv-21: Quantity Limits example — DAYBUE / EVRYSDI
    DAYBUE QL8 bottles/30 days
    DAYBUE STIX QL120 packets/30 days or 60 packets/30 days depending on pack
    EVRYSDI QL30 tablets/30 days (tablets) or 240 mls/30 days (solution)

    Authorization, Documentation, and Provider Steps

    Prior Authorization

    Obtain prior authorization for PA‑flagged drugs

    Certain drugs listed on the formulary are designated "PA" (Prior Authorization) in the Requirements/Limits column and require prior authorization before coverage will be provided; example: ARIKAYCE is listed with Requirements/Limits = LA, PA, QL (28 vials/28 days), SP.

    • Submit a prior authorization request for any drug shown with "PA" in Requirements/Limits.
    • Example drug entry: ARIKAYCE — Requirements/Limits = LA, PA, QL (28 vials/28 days), SP.
    Prior Authorization

    Follow PA and limited‑access/specialty requirements

    Some products are marked LA (Limited Availability) or LA plus PA/SP and must follow limited‑access or specialty distribution processes in addition to prior authorization when shown in Requirements/Limits; example: CRESEMBA is listed with Requirements/Limits = PA and SIRTURO with LA, SP.

    • Follow limited‑access (LA) distribution and specialty pharmacy (SP) routing where indicated.
    • Submit PA when LA or SP annotations accompany the drug entry (e.g., CRESEMBA = PA; SIRTURO = LA, SP).
    Prior Authorization

    Submit PA where the Requirements/Limits show "PA"

    Prior authorization is required for any product where the formulary's Requirements/Limits column includes the "PA" flag; providers must submit the authorization request prior to dispensing.

    • Check each formulary line for a "PA" annotation and submit the corresponding PA request.
    • Examples in this section include ISTURISA and JYNARQUE entries that list LA, PA, QL and require PA.
    Prior Authorization

    Prior authorization for specialty agents and higher‑tier products

    Many specialty or higher‑cost products are subject to prior authorization and additional controls (quantity limits, specialty routing); follow the PA and SP processes when prescribing these agents.

    • Examples include ATTRUBY (LA, PA, QL 112 tablets/28 days, SP) and ADEMPAS (LA, PA, QL 90 tablets/30 days, SP).
    • Confirm PA and any QL before authorizing or dispensing specialty drugs.
    Prior Authorization

    PA required for PA‑marked formulary entries

    Drugs explicitly marked "PA" in the Requirements/Limits column require prior authorization before coverage; examples in the formulary include ALYFTREK, BRINSUPRI, TRIKAFTA and other PA‑marked entries.

    • Do not assume coverage without an approved PA for PA‑marked medications.
    • Refer to each drug line for accompanying QL/LA/SP flags that may affect the PA process.
    Prior Authorization

    Submit PA for specified formulary entries with flags

    The formulary denotes PA, LA, QL, and SP next to products that are subject to administrative controls; providers must submit prior authorization requests for those entries as indicated.

    • Review the Requirements/Limits column on the formulary entry and submit PA/LA/SP/QL documentation as applicable.
    • Some products also list exact QL values that must be observed when requesting PA.
    Prior Authorization

    PA required for annotated products

    Several products listed in the formulary require prior authorization per their annotation (PA); examples include tasimelteon, SUNOSI, WAKIX, AUSTEDO and cladribine therapy packs where PA is shown.

    • Ensure PA requests reference the specific formulary product and pack size when applicable.
    • Cladribine (MAVENCLAD) therapy packs list PA and QL and must follow PA procedures.
    Prior Authorization

    Obtain PA for many branded/specialty drugs

    Prior authorization is required for many branded and specialty medications listed with PA and may be combined with LA, QL, or SP restrictions; check each line item and secure PA as needed.

    • Examples: INGREZZA (LA, PA, QL), MAVENCLAD (LA, PA, QL), VUMERITY (LA, PA, QL).
    • PA must be obtained prior to coverage to avoid claim denials.
    Prior Authorization

    Check PA on individual product lines

    Certain individual products show the "PA" flag in their line entry and therefore require prior authorization before coverage (e.g., ELYXYB, NURTEC, QULIPTA, and topiramate ER sprinkle formulations are noted with PA/QL where applicable).

    • Verify PA requirements for oral solution or specialty formulations that may have separate PA/QL designations.
    • Topiramate ER sprinkle formulations list PA and QL in the formulary extract.
    Prior Authorization

    Obtain PA for listed PA drugs (oral/liquid/ophthalmic)

    Many specialty, branded oral, liquid, and ophthalmic products include a "PA" annotation in Requirements/Limits and require prior authorization prior to coverage; review each entry and submit PA as applicable.

    • The Requirements/Limits column is the authoritative source for whether PA applies to a specific formulation.
    • If PA is indicated, do not dispense expecting coverage without approval.
    Prior Authorization

    PA required for select listed agents

    Some select agents in the formulary are annotated with "PA" and require prior authorization (examples include AKLIEF, ANZUPGO, CIBINQO, FILSUVEZ, HYFTOR, OPZELURA); submit PA requests for these agents when prescribing.

    • Confirm whether the entry also lists QL, LA, or SP and include that information in the PA submission.
    • Follow specialty distribution instructions (SP/LA) when present.
    Prior Authorization

    Secure PA for listed dermatology and specialty products

    Certain products in the dermatology and related segments are shown with "PA" in their Requirements/Limits and require prior authorization (examples: tazarotene cream/gel entries, ZELSUVMI, LUPKYNIS); obtain PA before dispensing.

    • When PA is indicated, submit supporting clinical documentation per payer instructions.
    • Check for accompanying QL, LA, or SP requirements on the same line.
    Note

    Index is a reference — check product entries for PA

    This index segment is a product index only and does not enumerate prior authorization rules; providers must refer to the specific formulary line or policy section referenced by the index to determine PA requirements.

    • Index entries list product name and references — they do not replace per‑product Requirements/Limits.
    • Consult the main formulary listings for PA/QL/LA/SP details.
    Note

    Index does not list PA requirements

    The index pages shown do not include prior authorization requirements themselves; no PA rules are listed in this index excerpt — consult the full formulary entry for authorization details.

    • Do not rely on the index alone to determine PA — the Requirements/Limits field on the product line is authoritative.
    • If unsure, contact Member Services for guidance.
    Step Therapy

    Follow step therapy for ST‑annotated drugs

    Drugs annotated with "ST" (Step Therapy) require members to try specified first‑line agents before later‑step drugs will be covered; where "ST" appears, follow the step‑therapy requirements before requesting coverage.

    • If a product is marked "ST", submit documentation of tried and failed first‑line agents as part of the authorization.
    • Example: ST is defined in the abbreviations list as requiring trial of earlier agents before coverage of later‑step drugs.
    Note

    No step‑therapy sequence listed here — verify before assuming

    No explicit step‑therapy pathways are provided in this extract for many products; where the formulary does not show a specific ST sequence, follow the line‑item flags (PA/QL/LA/SP) and consult full policy or prior‑authorization resources for step details.

    • When ST is not detailed on the line, do not assume a specific step sequence—request PA guidance from the payer or Member Services.
    • Tiering and access flags alone do not define step‑therapy sequences.
    Step Therapy

    Adhere to step therapy where the 'ST' flag appears

    Some products in the formulary are explicitly marked with 'ST' and require adherence to step therapy where shown; for example, KERENDIA is listed with Requirements/Limits = QL (30 tablets/30 days), ST and requires step‑therapy compliance.

    • Include evidence of prior therapy trials when submitting authorization for ST‑flagged agents.
    • KERENDIA (finerenone) is an example of a product with ST annotation.
    Step Therapy

    Submit step‑therapy documentation for ST‑flagged drugs

    Step therapy is indicated for select agents in the formulary (examples include AUVELITY QL/ST, FETZIMA ST, FLUOXETINE DR ST, TRINTELLIX ST); when ST is annotated, providers must document prior trials per the step requirement.

    • Submit documentation of failure, intolerance, or contraindication to first‑line agents to support PA for a later‑step drug.
    • Follow the plan's ST instructions where an ST flag is shown on the product line.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Contact Member Services for PA/coverage questions

    Members and providers may contact Member Services for coverage questions and next steps; the formulary indicates which drugs require PA, QL, ST, SP or LA and those annotations guide documentation and authorization workflows.

    • Member Services phone: 877-793-6253 (TTY: 711).
    • Use Member Services to clarify PA, QL, LA, SP and step‑therapy requirements before submitting prescriptions.
    Documentation Required

    Document indication and quantity when QL applies

    When quantity limits (QL) apply, providers should document the indication and the quantity requested; the formulary lists precise QL values (e.g., abacavir solution QL 960 mls/30 days, BIKTARVY QL 30 tablets/30 days).

    • Include clinical justification when requesting quantities above the listed QL.
    • Reference the exact QL value from the formulary in the PA or exception request.
    Documentation Required

    Meet PA/QL/LA/SP designations listed per drug

    Prior authorization (PA), quantity limits (QL), limited access (LA), and specialty pharmacy (SP) designations are applied to listed products and must be met per the drug-specific Requirements/Limits.

    • Use the Requirements/Limits annotations on each line as the basis for authorization and dispensing actions.
    • Do not dispense assuming coverage if PA or other flags are present without prior approval.
    Documentation Required

    Provide required documentation with PA requests

    Prescribers should supply supporting documentation required for prior authorization where indicated; the formulary entries show 'Requirements/Limits = PA, QL, LA, SP' for specific products and that documentation must accompany PA submissions.

    • Include clinical notes, prior treatment history, and quantity rationale as applicable.
    • For LA/SP drugs, coordinate with the specialty pharmacy and include any distributor‑specific paperwork.
    Documentation Required

    Follow PA/LA/SP and QL requirements on the formulary

    Prescribers must follow payer requirements for drugs flagged with PA, LA, SP and adhere to specified quantity limits (examples include ALYFTREK QL 84 tablets/28 days and TRIKAFTA QL 56 packets/28 days); follow the formulary instructions when requesting coverage.

    • When a drug lists QL, ensure the prescribed quantity does not exceed the QL unless a PA justification is submitted.
    • For LA and SP entries, use the designated distribution channel and include necessary documentation in the PA.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Per-Drug Quantity Limits

    ProductFormulation / StrengthQuantity Limit
    ARIKAYCEamikacin sulfate liposome inhalation suspension 590 mg/8.4 mL — 28 vials28 vials/28 days
    inv-113: abacavir sulfate soln 20 mg/ml — 960 mls
    abacavir sulfate oral solution 20 mg/mL QL960 mls/30 days
    Associated productsAbacavir tablets also listed with separate QLs (e.g., 60 tablets/30 days)
    Formulary contextQuantity limit shown in Requirements/Limits column for liquid formulation
    inv-114: BIKTARVY — 30 tablets
    BIKTARVY quantity limit30 tablets/30 days
    Formulationbictegravir-emtricitabine-tenofovir AF combination tablets
    Requirements/LimitsQL indicated in formulary entry
    inv-115: PAXLOVID — 11-30 tablets (pack dependent)
    PAXLOVID quantity limit11–30 tablets (pack dependent)
    Pack-based limitsDifferent pack sizes have QL entries (11, 20, 30 tablets per 30 days)
    Formulary annotationQL shown per pack in Requirements/Limits column
    inv-116: SUNLENCA therapy pack — 4-5 tablets
    SUNLENCA therapy pack quantity4–5 tablets (therapy pack)
    Formulationlenacapavir therapy packs and tablets listed with LA, QL, SP
    TimeframeQL shown as 4 tablets/365 days for some entries
    inv-117: XOFLUZA — 2 tablets
    XOFLUZA quantity limit2 tablets (therapy pack)
    IndicationSingle-course antiviral therapy pack — QL reflects pack size
    Formulary noteQL specified in Requirements/Limits column
    inv-118: CRENESSITY - crinecerfont cap — 60 capsules
    CRENESSITY — crinecerfont capsules QL60 capsules/30 days
    CRENESSITY — crinecerfont oral solution QL120 mLs/30 days
    CRENESSITY — crinecerfont capsule QL (actionable)60 capsules/30 days
    inv-119: CRENESSITY - crinecerfont oral soln — 120 mls
    CRENESSITY oral solution limit120 mLs/30 days
    Formulationcrinecerfont oral solution 50 mg/mL
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-120: GALAFOLD - migalastat — 14 capsules
    GALAFOLD quantity limit14 capsules/28 days
    Formulationmigalastat HCl capsules (GALAFOLD)
    Requirements/LimitsLA, PA, QL noted in entry
    inv-121: JYNARQUE - tolvaptan — 56 tablets
    JYNARQUE quantity limit56 tablets/28 days
    Formulationtolvaptan therapy packs and tablets; QL varies by pack/strength
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-122: KERENDIA - finerenone — 30 tablets
    KERENDIA (finerenone) QL30 tablets/30 days
    Formulationfinerenone tablets 10/20/40 mg
    AuthorizationMarked ST (step therapy) where indicated
    inv-123: QBRELIS - lisinopril oral soln 1 mg/ml — 1200 mls
    QBRELIS (lisinopril oral solution) QL1200 mLs/30 days
    FormulationLisinopril oral solution 1 mg/mL (QBRELIS)
    Requirements/LimitsPA, QL indicated in formulary entry
    inv-124: DIURIL - chlorothiazide susp 250 mg/5ml — 1200 mls
    DIURIL (chlorothiazide) QL1200 mLs/30 days
    Formulationchlorothiazide suspension 250 mg/5 mL
    AuthorizationPA and QL noted in Requirements/Limits
    inv-125: FUROSEMIDE - furosemide oral soln 10 mg/ml — 1800 mls
    FUROSEMIDE oral solution QL1800 mLs/30 days
    FormulationFurosemide oral solution 10 mg/mL
    Requirements/LimitsPA and QL listed for liquid formulation
    inv-126: ADEMPAS - riociguat — 90 tablets
    ADEMPAS (riociguat) QL90 tablets/30 days
    Formulationriociguat tablets (various strengths)
    Requirements/LimitsLA, PA, QL, SP indicated in entry
    inv-127: ambrisentan (Letairis) — 30 tablets
    ambrisentan (Letairis) QL30 tablets/30 days
    Formulationambrisentan tablets 5 mg, 10 mg
    Requirements/LimitsLA, PA, QL, SP where indicated
    inv-128: CORLANOR - ivabradine oral soln 5 mg/5ml — 600 mls
    CORLANOR oral solution QL600 mLs/30 days
    FormulationIvabradine oral solution 5 mg/5 mL (Corlanor)
    Requirements/LimitsLA, PA, QL indicated
    inv-129: ENTRESTO - sacubitril-valsartan sprinkle cap — 240 capsules
    ENTRESTO sprinkle capsules QL240 capsules/30 days
    Formulationsacubitril-valsartan sprinkle capsules
    Requirements/LimitsPA and QL noted in formulary entry
    inv-130: TYVASO DPI MAINTENANCE KI - treprostinil inh powder — 112 cartridges
    TYVASO DPI Maintenance kit QL112 cartridges
    ProductTreprostinil inhalation powder cartridges (TYVASO DPI)
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-131: TYVASO DPI TITRATION KIT — 252 cartridges
    TYVASO DPI titration kit QL252 cartridges
    KitTitration kit with multiple cartridge counts; QL applies per kit
    TimeframeQL entry indicates per 180 days for some kits
    inv-132: UPTRAVI - selexipag — 60 tablets
    UPTRAVI (selexipag) QL60 tablets/30 days
    Titration packUPTRAVI titration pack QL = 1 package (per 180 days)
    Requirements/LimitsLA, PA, QL, SP where indicated
    inv-133: UPTRAVI TITRATION PACK — 1 package
    UPTRAVI titration pack1 package (QL)
    UseTherapy titration pack; QL and LA/PA apply
    DistributionSpecialty pharmacy (SP) indicated
    inv-134: VERQUVO - vericiguat — 30 tablets
    VERQUVO (vericiguat) QL30 tablets/30 days
    FormulationVericiguat tablets 2.5/5/10 mg
    Requirements/LimitsPA and QL listed in entry
    inv-135: VYNDAMAX - tafamidis — 30 capsules
    VYNDAMAX (tafamidis) QL30 capsules/30 days
    FormulationTafamidis capsules 61 mg
    AuthorizationPA and QL indicated; specialty (SP) noted
    inv-136: YUTREPIA - treprostinil sodium inhal cap — 112 capsules
    YUTREPIA QL112 capsules/28 days
    FormulationTreprostinil sodium inhalation capsules (various strengths)
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-137: ASMANEX TWISTHALER — 1 inhaler
    ASMANEX TWISTHALER QL1 inhaler/30 days
    ProductMometasone inhaler (Asmanex Twisthaler)
    Formulary noteQL specified in Requirements/Limits
    inv-138: ATROVENT HFA — 2 inhalers
    ATROVENT HFA QL2 inhalers/30 days
    ProductIpratropium bromide HFA aerosol (Atrovent HFA)
    Coverage noteQuantity limit enforced per formulary entry
    inv-139: BREO ELLIPTA — 1 inhaler
    BREO ELLIPTA QL1 inhaler/30 days
    ProductFluticasone furoate-vilanterol (Breo Ellipta)
    Formulary entryQL listed in Requirements/Limits
    inv-140: ALYFTREK — 84 tablets
    ALYFTREK QL84 tablets/28 days
    Formulationvanzacaftor-tezacaftor-deutivacaftor tablets
    AuthorizationLA, PA, QL, SP indicated
    inv-141: TRIKAFTA — 56 packets (and alternative formulations)
    TRIKAFTA packets QL56 packets/28 days
    TRIKAFTA tablets QL (alt formulations)90 tablets/30 days
    Most actionable QL56 packets/28 days (common packet-based limit)
    inv-142: TRIKAFTA (alternative formulations) — 90 tablets
    TRIKAFTA alternative formulation QL90 tablets/30 days
    ContextApplies to tablet formulations/alternate dosing forms listed in entry
    Requirements/LimitsLA, PA, QL, SP where noted
    inv-143: BRINSUPRI — 30 tablets
    BRINSUPRI QL30 tablets/30 days
    FormulationBrensocatib tablets
    Requirements/LimitsLA, PA, QL, SP where indicated
    inv-144: esomeprazole packets — 60 packets
    Esomeprazole packets QL60 packets/30 days
    FormulationEsomeprazole magnesium delayed-release suspension packets (Nexium)
    Requirements/LimitsQL indicated in entry
    inv-145: famotidine suspension — 2400 mL
    Famotidine suspension QL2400 mLs/30 days
    FormulationFamotidine oral suspension 40 mg/5 mL
    Requirements/LimitsPA and QL indicated for suspension formulation
    inv-146: pirfenidone (Esbriet) capsules — 180 capsules
    Pirfenidone (Esbriet) capsules QL180 capsules/30 days
    FormulationPirfenidone capsules (Esbriet)
    Requirements/LimitsQL specified in formulary entry
    inv-147: sevelamer carbonate packet 0.8 gm — 510 packets
    Sevelamer carbonate packet QL510 packets/30 days
    FormulationSevelamer carbonate packet 0.8 g
    Requirements/LimitsQL indicated in entry
    inv-148: VOWST — 12 capsules
    VOWST QL (annual)12 capsules/365 days
    FormulationFecal microbiota spores, live - VOWST capsules
    Requirements/LimitsLA, PA, QL, SP indicated in formulary entry
    inv-149: GEMTESA (vibegron) — 30 tablets/30 days
    GEMTESA (vibegron) QL30 tablets/30 days
    FormulationVibegron 75 mg tablets
    Requirements/LimitsQL noted in entry
    inv-150: mirabegron (MYRBETRIQ) tablets — 30 tablets/30 days
    MYRBETRIQ (mirabegron) tablets QL30 tablets/30 days
    Alternate formulation QLGranules formulation QL = 300 mLs/28 days
    Formulary noteQL entries vary by formulation
    inv-151: ESTRACE (estradiol vaginal cream) — 255 grams/365 days
    ESTRACE (estradiol vaginal cream) QL255 grams/365 days
    FormulationEstradiol vaginal cream 0.01%
    Requirements/LimitsQL shown in Requirements/Limits column
    inv-152: VOWST — 12 capsules/365 days (duplicate)
    VOWST annual QL (duplicate)12 capsules/365 days
    NoteSame QL appears in multiple entries of the formulary
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-153: Aripiprazole ODT 10 mg, 15 mg — 60 tablets
    Aripiprazole ODT QL60 tablets/30 days
    FormulationAripiprazole orally disintegrating tablets 10 mg, 15 mg
    Requirements/LimitsQL indicated in entry
    inv-154: Aripiprazole tablets (Abilify) — 30 tablets
    Aripiprazole (Abilify) QL30 tablets/30 days
    FormulationAripiprazole tablets (various strengths)
    Requirements/LimitsQL shown in Requirements/Limits column
    inv-155: Clozapine ODT/tablets — examples include 90,120,150,180,270 tablets/30 days
    Clozapine ODT/tablets examplesExamples include 90, 120, 150, 180, 270 tablets/30 days depending on strength
    FormulationClozapine orally disintegrating tablets and tablets
    Requirements/LimitsQL varies by strength as listed
    inv-156: Risperidone solution — 480 mls
    Risperidone solution QL480 mLs/30 days
    FormulationRisperidone oral solution 1 mg/mL
    Requirements/LimitsQL specified in entry
    inv-157: Methylphenidate solutions and chewables — examples include 360 mls/30 days, 450 mls/30 days; chewable tablets up to 180 tablets/30 days
    Methylphenidate solutions/chewables examplesExamples include 360 mLs/30 days, 450 mLs/30 days; chewable tablets up to 180 tablets/30 days
    FormulationsOral solutions and chewable tablets across methylphenidate products
    Requirements/LimitsQL entries vary by product and strength
    inv-158: AUSTEDO XR — 30 tablets
    AUSTEDO XR QL30 tablets/30 days
    FormulationDeutetrabenazine extended-release tablets
    Requirements/LimitsPA and QL listed; specialty noted
    inv-159: VERSACLOZ (clozapine suspension) — 540 mls
    VERSACLOZ (clozapine suspension) QL540 mLs/30 days
    FormulationClozapine suspension (Versacloz)
    Requirements/LimitsQL and ST noted where applicable
    inv-160: INGREZZA (valbenazine) — 28-30 capsules
    INGREZZA (valbenazine) QL28–30 capsules/30 days
    FormulationValbenazine capsules and therapy packs
    Requirements/LimitsLA, PA, QL indicated for therapy packs and capsules
    inv-161: sodium oxybate (Xyrem) — 540 mls
    Sodium oxybate (Xyrem) QL540 mLs/30 days
    FormulationSodium oxybate oral solution (Xyrem/XYWAV/LUMRYZ)
    Requirements/LimitsLA, PA, QL indicated; specialty pharmacy noted
    inv-162: VUMERITY (diroximel fumarate) — 120 capsules
    VUMERITY QL120 capsules/30 days
    FormulationDiroximel fumarate delayed-release capsules (VUMERITY)
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-163: ZEPOSIA (ozanimod) — 30 capsules
    ZEPOSIA QL30 capsules/30 days
    FormulationOzanimod capsules and starter kits
    Requirements/LimitsPA, QL, SP where indicated
    inv-164: fentanyl transdermal patch — 15 patches
    Fentanyl transdermal patch QL15 patches/30 days
    FormulationFentanyl transdermal patches (72-hour)
    Requirements/LimitsPA and QL indicated
    inv-165: ketorolac tromethamine tab 10 mg — 20 tablets/5 days
    Ketorolac tromethamine tablets QL20 tablets/5 days
    FormulationKetorolac tromethamine 10 mg tablets
    Time-limited QLShort-course limit (5 days) enforced
    inv-166: eletriptan (Relpax) — 12 tablets/30 days
    Eletriptan (Relpax) QL12 tablets/30 days
    FormulationEletriptan hydrobromide tablets
    Requirements/LimitsQL listed in migraine products section
    inv-167: narratriptan — 18 tablets/30 days
    Naratriptan QL18 tablets/30 days
    FormulationNaratriptan tablets
    Requirements/LimitsQL in migraine products listings
    inv-168: NURTEC (rimegepant) — 16 tablets/30 days
    NURTEC (rimegepant) QL16 tablets/30 days
    FormulationRimegepant 75 mg orally disintegrating tablets
    Requirements/LimitsPA and QL indicated
    inv-169: QULIPTA (atogepant) — 30 tablets/30 days
    QULIPTA (atogepant) QL30 tablets/30 days
    FormulationAtogepant tablets (various strengths)
    Requirements/LimitsPA and QL indicated in entry
    inv-170: sumatriptan nasal spray — 12 inhalers/30 days
    Sumatriptan nasal spray QL12 inhalers/30 days
    FormulationSumatriptan nasal spray 5 mg/act, 20 mg/act
    Requirements/LimitsQL listed in migraine products section
    inv-171: FINTEPLA (fenfluramine) oral solution — 360 mls/30 days
    FINTEPLA oral solution QL360 mLs/30 days
    FormulationFenfluramine hydrochloride oral solution 2.2 mg/mL
    Requirements/LimitsLA, PA, QL indicated
    inv-172: pregabalin (various strengths) — varies by strength
    Pregabalin QLs vary by strengthExamples include 360/270/180/90/60 capsules per 30 days depending on strength
    FormulationsVaries across immediate-release and other formulations
    Requirements/LimitsQL entries provided per-strength in formulary
    inv-173: DAYBUE / DUVYZAT / EVRYSDI / RADICAVA ORS and similar specialty products
    DAYBUE / DUVYZAT / EVRYSDI / RADICAVA ORS — explicit QLsExamples include 8 bottles/30 days; 3 bottles/30 days; 30 tablets/30 days; 50 mLs/28 days
    ProductsSpecialty oral/neuro agents with formulation-specific QLs
    DistributionLA/PA/QL and SP flags commonly apply
    inv-174: DAYBUE (trofinetide oral soln) — 8 bottles
    DAYBUE (trofinetide) QL8 bottles/30 days
    FormulationTrofinetide oral solution 200 mg/mL
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-175: DAYBUE STIX — 120 or 60 packets
    DAYBUE STIX QL120 packets/30 days or 60 packets/30 days depending on pack
    FormulationPowder packets (DAYBUE STIX) in multiple pack sizes
    Requirements/LimitsPA and QL indicated; specialty distribution noted
    inv-176: EVRYSDI — 30 tablets/30 days or 240 mls/30 days
    EVRYSDI QL (tablets)30 tablets/30 days
    EVRYSDI QL (solution)240 mLs/30 days
    Requirements/LimitsLA, PA, QL, SP indicated for formulations
    inv-177: RADICAVA ORS — 50 mls/28 days (regular); 70 mls/180 days (starter kit)
    RADICAVA ORS QL (regular)50 mLs/28 days
    RADICAVA ORS QL (starter kit)70 mLs/180 days
    FormulationEdaravone oral suspension 105 mg/5 mL
    inv-178: eltrombopag (Promacta) — 30–60 packets or tablets per 30 days
    Eltrombopag (Promacta) QL30–60 packets or tablets per 30 days depending on strength
    FormulationPowder for suspension and tablets; QL varies by strength
    Requirements/LimitsPA, QL, SP often apply
    inv-179: PYRUKYND (mitapivat) — 56 tablets/28 days
    PYRUKYND QL56 tablets/28 days
    FormulationMitapivat tablets (PYRUKYND)
    Requirements/LimitsLA, PA, QL, SP indicated
    inv-180: OXERVATE (cenegermin) — 56 vials/112 days
    OXERVATE QL56 vials/112 days
    FormulationCenegermin ophthalmic solution (OXERVATE)
    Requirements/LimitsQL specified in ophthalmic agents listings
    inv-181: RHOPRESSA/ROCKLATAN (netarsudil-containing) — 2.5 mls/30 days
    RHOPRESSA/ROCKLATAN QL2.5 mLs/30 days
    FormulationsNetarsudil ophthalmic solution (RHOPRESSA) and netarsudil-latanoprost (ROCKLATAN)
    Requirements/LimitsQL shown in ophthalmic agents section
    inv-182: netarsudil dimesylate (RHOPRESSA) — 2.5 mls
    Netarsudil (RHOPRESSA) QL2.5 mLs/30 days
    Product typeNetarsudil ophthalmic solution 0.02%
    Formulary noteQL enforced per 30-day period
    inv-183: netarsudil dimesylate-latanoprost (ROCKLATAN) — 2.5 mls
    ROCKLATAN QL2.5 mLs/30 days
    FormulationNetarsudil dimesylate-latanoprost ophthalmic solution
    Requirements/LimitsQL listed in ophthalmic agents section
    inv-184: latanoprostene bunod (VYZULTA) — 2.5 mls
    VYZULTA QL2.5 mLs/30 days
    FormulationLatanoprostene bunod ophthalmic solution 0.024%
    Requirements/LimitsQL indicated in formulary entry
    inv-185: abrocitinib (CIBINQO) — 30 tablets
    CIBINQO (abrocitinib) QL30 tablets/30 days
    FormulationAbrocitinib tablets 50/100/200 mg
    Requirements/LimitsQL indicated in dermatology agents listing
    inv-186: fluocinolone acetonide oil (Derma-smoothe) scalp/body — 118.28 ml
    Fluocinolone oil QL118.28 mLs/30 days
    FormulationFluocinolone acetonide oil (Derma-smoothe) scalp/body
    Requirements/LimitsQL listed in topical products section
    inv-187: lidocaine patch 5% (Lidoderm) — 90 patches
    Lidocaine patch (Lidoderm) QL90 patches
    FormulationLidocaine 5% patch
    Requirements/LimitsQL specified in formulary entry
    inv-188: various (see excerpts) — common QL examples
    Various topical/other QLs (examples)Examples include QL 120 mLs/30 days for triamcinolone lotion; QL 454 grams/30 days for triamcinolone cream/ointment; ZELSUVMI QL = 2 kits/84 days
    ContextMultiple QLs for topical, kit, and specialty items appear across entries
    ActionRefer to specific line item for exact QL and timeframe

    Specialty Pharmacy and Distribution

    Note
    Note
    Note

    Formulary Background and Scope

    Background: This formulary lists covered anti‑infective agents and a broad range of other drugs organized by therapeutic class, with an assigned drug tier and utilization management annotations. The document shows per‑product designations such as PA (prior authorization), QL (quantity limit), ST (step therapy), SP (specialty pharmacy) and LA (limited availability) that guide coverage, dispensing channel, and required documentation for members and prescribers.

    Definitions and Abbreviations

    inv-79: PA — Prior Authorization definition
    PA — Prior AuthorizationThe plan requires approval before you fill your prescription; failure to obtain PA may result in non‑coverage.
    QL — Quantity LimitThe plan limits the amount of a drug that will be covered over a specified time period.
    SP — Specialty DrugSpecialty drugs may require special handling, monitoring, and education and often route through specialty pharmacy.
    ST — Step TherapyThe plan may require trying specified first-line agents before covering a later-step drug.
    LA — Limited AvailabilityDrug may be available only at select pharmacies (limited access).
    inv-80: QL — Quantity Limit definition
    QL — Quantity Limit definitionThe plan limits the amount of the drug that we will cover (quantity per time period).
    ExampleShown in entries as QL (e.g., 30 tablets/30 days).
    EnforcementClaims exceeding QL may require prior authorization or be denied.
    inv-81: SP — Specialty Drug definition
    SP — Specialty Drug definitionSpecialty drugs may require special handling, monitoring, and unique education prior to use and are often dispensed via specialty pharmacy.
    DistributionEntries flagged 'SP' indicate specialty pharmacy routing.
    Administrative requirementsSP drugs frequently carry PA, LA, or QL annotations.
    inv-82: ST — Step Therapy definition
    ST — Step Therapy definitionStep Therapy requires trying specified first‑line drugs before covering alternative agents.
    Operational noteDrugs annotated 'ST' in the formulary are subject to step therapy requirements.
    Provider actionProviders should document prior trials when requesting coverage for later‑step agents.
    inv-83: LA — Limited Availability definition
    LA — Limited Availability definitionLimited Availability indicates a drug may be available only at designated pharmacies or via restricted distribution.
    ImplicationLA entries may require specialty distribution or prior authorization.
    ReferCheck the Requirements/Limits column for LA details per product.
    inv-84: PA / QL / LA / SP — Combined abbreviation key
    Combined abbreviations (PA / QL / LA / SP)PA = Prior Authorization; QL = Quantity Limit; LA = Limited Availability; SP = Specialty Pharmacy routing
    UsageThese abbreviations appear in the Requirements/Limits column for line‑item entries.
    Provider implicationFollow per‑drug flags for authorization and dispensing requirements.

    Step Therapy Requirements

    Step therapy summaryRequirement
    General step therapy policyMembers must try specified first-line agents when a drug is annotated 'ST' before a later-step drug will be covered.
    ScopeNotes
    Step therapy pathways in excerptNo explicit step therapy sequences are listed in this excerpt; only tiering and Requirements/Limits flags (PA, QL, LA, SP) are provided.
    ProductAnnotation / FlagNotes
    KERENDIA (finerenone)ST, QL (30 tablets/30 days)Marked 'ST' — step therapy applies where annotated; quantity limit 30 tablets/30 days.
    Products notedAccess flagsStep sequence present?
    JUXTAPID; NEXLETOL / NEXLIZETLA, SP (JUXTAPID); PA, QL (NEXLETOL/NEXLIZET)Explicit step sequence not provided in these chunks.
    Excerpt summaryUtilization flags presentStep therapy details
    Formulary excerpt linesPA, QL, LA, SP flags appear on many productsNo explicit step therapy steps listed in these chunks.
    ObservationImplication
    Selected agents show 'ST' annotationStep therapy requirement applies to those selected agents (ST flag present).
    ExamplesAnnotation
    FANAPT titration packs; SECUADO; BELSOMRAEntries include 'ST' indicating subject to step therapy prior to approval.
    Product examplesAnnotation / Note
    HORIZANT (gabapentin enacarbil); Gralise entriesAnnotated with ST and QL — step therapy applies where shown.
    Product groupStep therapy present?
    Topiramate extended-release sprinkle formulationsListed with PA and QL but explicit step requirements are not present in this excerpt.
    General noteDetail
    Overall excerpt observationNo explicit step-therapy sequences are listed in this extract; entries indicate PA/QL/LA/SP but not step order.
    Authorization triggerEffect on coverage
    PA required annotationsPrior authorization is required before coverage for products listed with 'PA'.
    Product typesManagement flags / Step detail
    Some specialty / high-cost agents (e.g., lenalidomide, voclosporin)Designated SP or LA and require PA/QL; explicit step sequences are not provided in these chunks.

    Document Dates and Revision Notes

    2026-04-01effective_dateLatest

    Formulary updated and effective date recorded as April 1, 2026.

    2026-04-26document_identifier

    Document footer indicates local formulary identifier and date 'local-246-formulary-2026-emblemhealth 4/26'.